Another drug developer for the animal health field is going public. Parnell Pharmaceuticals outlined plans to raise $57.5 million in an IPO designed to fuel its work on new therapies for family pets as well as production animals.
Fast-growing R&D services outfit WuXi PharmaTech is marching ahead with plans to wrap a $250 million venture fund aimed at U.S. and China life sciences companies. WuXi filed documents with the SEC last week outlining the goal for WuXi Healthcare Ventures Fund II, which it’s already made a $50 million anchor investment in. …read more […]